Chronic sirolimus therapy for lymphangioleiomyomatosis

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 12, 2014, Pages 1332-1333

  McCormack, Francis X ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAPAMYCIN;

CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHANGIOLEIOMYOMATOSIS; QUALITY OF LIFE; TREATMENT RESPONSE; DRUG EFFECTS; LUNG; LUNG NEOPLASMS;

HUMANS; LUNG; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; SIROLIMUS;

EID: 84919360810     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201411-2032ED     Document Type: Editorial

References (9)

1. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: Calling it what it is: A low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012;186: 1210-1212.
2. Henske EP, McCormack FX. Lymphangioleiomyomatosis -A wolf in sheep's clothing. J Clin Invest 2012;122: 3807-3816.
3. Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T. Lymphangioleiomyomatosis: A disease involving the lymphatic system. Lymphat Res Biol 2010;8: 21-31.
4. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al.; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364: 1595-1606.
5. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011;154: 797-805.
6. Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014;190: 1273-1282.
7. Yao J, Taveira-DaSilva AM, Colby TV, Moss J. CT grading of lung disease in lymphangioleiomyomatosis. AJR Am J Roentgenol 2012;199: 787-793.
8. Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, Doi T, Iwakami S, Takahashi K, Seyama K, et al. Efficacy and safety of lowdose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig 2013;51: 175-183.
9. Young L, Lee H-S, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, et al.; MILES Trial Group. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013;1: 445-452.